Extended Low-Dose Apixaban After Provoked VTE: Marc Carrier Spotlights Major NEJM Results
Marc Carrier, Professor at Ottawa Hospital Research Institute, has posted on X:
”New in NEJM:
In patients with provoked VTE + enduring risk factors, extended low-dose apixaban (2.5 mg bid ×12 months): reduced recurrent VTE risk by nearly 90% (1.3% vs 10.0%): HR 0.13
Major bleeding was rare (1 pt).”
Find the full study here.
Title: Apixaban for Extended Treatment of Provoked Venous Thromboembolism
Authors: Gregory Piazza, Behnood Bikdeli, Arvind K. Pandey, Darsiya Krishnathasan, Candrika D. Khairani, Antoine Bejjani, Ruth H. Morrison, Heather Hogan, Sina Rashedi, Mariana Pfeferman, Junyang Lou, John Fanikos, Nicole Porio, Lisa Rosenbaum, Piotr Sobieszczyk, Zhou Lan, Marie Gerhard-Herman, Umberto Campia, and Samuel Z. Goldhaber
Stay updated with Hemostasis Today.
-
Jan 20, 2026, 16:34Fernanda Orsi Explores Brazilian Registry of Thrombotic Thrombocytopenic Purpura
-
Jan 20, 2026, 16:15Tareq Abadl on Bacterial Contamination of Platelets
-
Jan 20, 2026, 15:53Ruzanna Papyan on Neuroblastoma Risk Stratification in Real-World Settings
-
Jan 20, 2026, 13:35Omar Shaltout On Stories Behind Memorable Cases
-
Jan 20, 2026, 13:25Omotola Olasupo and Colleagues Present Comparative Safety of Hemophilia Therapies in Canada
-
Jan 20, 2026, 13:15Benjamin YQ Tan on Precision Lipid Management After Stroke
-
Jan 20, 2026, 13:08Antonio Paul on Blame Game in Transplantation: HLA vs Microbes
-
Jan 20, 2026, 12:33Dario Tuccinardi on Obesity as Cardiovascular Treatment Target
-
Jan 20, 2026, 12:18Ed Shovelin on CRP-A Utilization in Diverse Research Areas